49688 Federal Register / Vol. 73, No. 164 / Friday, August 22, 2008 / Notices 

pending foreign counterparts [HHS Ref. 

No. E–099–1996/0]; 

4. U.S. Patent No. 6,001,349 issued 

December 14, 1999 as well as issued and 

pending foreign counterparts [HHS Ref. 

No E–200–1990/3–US–01]; 

5. U.S. Patent No.6,165,460 issued 

December 26, 2000; as well as issued 

and pending foreign counterparts [HHS 

Ref. No E–200–1990/4–US–01]; 

6. U.S. Patent No. 7,118,738 issued 

October 10, 2006 as well as issued and 

pending foreign counterparts [HHS Ref. 

No E–154–1998/0–US–07]; 

7. PCT Application No. PCT/US97/ 

12203 filed July 15, 1997 [HHS Ref. No 

E–259–1994/3–PCT–02]; 

8. U.S. Patent Application Nos. 10/ 

197,127. and 08/686,280 filed July 17, 

2002 and July 25, 1996 [HHS Ref. No E–

259–1994/3–US–08 and /4–US–01]; 

9. U.S. Patent No. 6,946,133 issued 

September 20, 2005 as well as issued 

and pending foreign counterparts [HHS 

Ref. No E–062–1996/0–US–01]; 

10. U.S. Patent Application No. 11/ 

606,929 filed December 1, 2006 [E–062–

1996/0–US–11]; 

11. U.S. Patent Nos. 6,893,869, 

6,548,068 and 6,045,802 issued May 17, 

2005, April 15, 2003 and April 4, 2000 

respectively, as well as issued and 

pending foreign counterparts [HHS Ref. 

Nos. E–260–1994/1–US–03, US–02, US–

01]; and 

12. U.S. Patent. Application No. 11/ 

090,686 filed March 8, 2005 [HHS Ref. 

No E–260–1994/1–US–04]. 

Cooperative Research and Development 

Agreement (CRADA) Opportunities 

A CRADA partner for the further codevelopment of this technology is 

currently being sought by the Laboratory 

of Tumor Immunology and Biology, 

Center for Cancer Research, NCI. The 

CRADA partner will (a) generate and 

characterize recombinant poxviruses 

expressing specific tumor-associated 

antigens, cytokines, and/or T-cell 

costimulatory factors, (b) analyze the 

recombinant poxviruses containing 

these genes with respect to appropriate 

expression of the encoded gene 

product(s), (c) supply adequate amounts 

of recombinant virus stocks for 

preclinical testing, (d) manufacture and 

test selected recombinant viruses for use 

in human clinical trials (with the 

exception of trials for prostatic diseases 

and melanoma), (e) submit Drug Master 

Files detailing the development, 

manufacture, and testing of live 

recombinant vaccines to support the 

NCI-sponsored IND and/or companysponsored IND, (f) supply adequate 

amounts of clinical grade recombinant 

poxvirus vaccines for clinical trials 

conducted at the NCI Center for Cancer 

Research (CCR), and (g) provide 

adequate amounts of vaccines for 

extramural clinical trials, if agreed upon 

by the parties, and conduct clinical 

trials under company-sponsored or NCIsponsored INDs. NCI will (a) provide 

genes of tumor-associated antigens, 

cytokines and other immunostimulatory 

molecules for incorporation into 

poxvirus vectors, (b) evaluate 

recombinant vectors in preclinical 

models alone and in combination 

therapies, and (c) conduct clinical trials 

(with the exception of trials for prostatic 

diseases and melanoma) of recombinant 

vaccines alone and in combination 

therapies. 

Dated: August 14, 2008 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–19462 Filed 8–21–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Neurological 

Disorders and Stroke Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Neurological Disorders and Stroke Council; 

Clinical Trials Subcommittee. 

Date: September 18, 2008. 

Closed: 8 a.m. to 9 a.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C Wing, 

Conference Room 10, Bethesda, MD 20892. 

Open: 9 a.m. to 10 a.m. 

Agenda: To discuss clinical trials policy. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C Wing, 

Conference Room 10, Bethesda, MD 20892. 

Contact Person: Deborah G Hirtz, MD, 

Acting Director, Clinical Trials Cluster, 

National Institute of Neurological, Disorders 

and Stroke, National Institute of Health, 6001 

Executive Blvd., Suite 2212, Bethesda, MD 

20892, (301) 496–5821, hirtz@ninds.nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: 

www.ninds.nih.gov, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to NeurologicalDisorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: August 15, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–19442 Filed 8–21–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meetings 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of meetings of the 

National Advisory Neurological 

Disorders and Stroke Council. 

The meetings will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Advisory 

Neurological Disorders and Stroke Council, 

Training, Career Development, and Special 

Programs Subcommittees. 

Date: September 17, 2008. 

Time: 8 p.m. to 10 p.m. 


jlentini on PROD1PC65 with NOTICES